EU Advises Use Of Pandemic Flexibilities For Trials In Ukraine
Russian CRO Body Issues Recommendations
Executive Summary
Amid the continuing conflict and the Russian shelling of hospitals in Ukraine, regulatory bodies, health authorities and clinical research organizations are issuing guidance on how to deal with the impact on clinical trials in both Ukraine and Russia.
You may also be interested in...
EMA Explains How To Minimize Trial Disruptions In Face Of Political Conflicts, Natural Disasters
With major disruptions to clinical trials becoming more commonplace due to political conflicts and natural disasters, the European Medicines Agency has developed guidance to help sponsors make risk-based adjustments to manage ongoing studies.
Trial Sponsors Seek New Countries As Russian Market ‘Falls Into The Abyss’
The Russian clinical trials organization ACTO says the “gloomy” prospects for multinational clinical trials in the country have led many sponsors to postpone the initiation of new studies or abandon them entirely in favor of other markets.
Ukraine War Could Spur Changes In The Clinical Trial Paradigm
Decentralized trials are a way to help displaced Ukrainians remain in studies and could encourage greater participation from individuals in other countries, those overseeing sites in Ukraine say.